References
- Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat. Med. 17(3), 297–303 (2011).
- Stephens PJ, Tarpey PS, Davies H et al.; Oslo Breast Cancer Consortium (OSBREAC). The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403), 400–404 (2012).
- Ellis MJ, Ding L, Shen D et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403), 353–360 (2012).
- Banerji S, Cibulskis K, Rangel-Escareno C et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486(7403), 405–409 (2012).
- Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403), 395–399 (2012).
- Curtis C, Shah SP, Chin SF et al.; METABRIC Group. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403), 346–352 (2012).
- Ross-Innes CS, Stark R, Teschendorff AE et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481(7381), 389–393 (2012).
- Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407), 330–337 (2012).
- Seshagiri S, Stawiski EW, Durinck S et al. Recurrent R-spondin fusions in colon cancer. Nature 488(7413), 660–664 (2012).
- Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark. Med. 4(4), 583–586 (2010).
- Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev. Med. Devices 7(6), 723–726 (2010).
- Ecker JR, Bickmore WA, Barroso I, Pritchard JK, Gilad Y, Segal E. Genomics: ENCODE explained. Nature 489(7414), 52–55 (2012).
- Pennisi E. Genomics. ENCODE project writes eulogy for junk DNA. Science 337(6099), 1159–1161 (2012).
- Gerstein MB, Kundaje A, Hariharan M et al. Architecture of the human regulatory network derived from ENCODE data. Nature 489(7414), 91–100 (2012).
- Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8), 1039–1043 (2010).
- Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 11(2), 81–92 (2011).
- Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12(1), 56–68 (2011).
- Roukos DH. Disrupting cancer cells’ biocircuits with interactome-based drugs: is ‘clinical’ innovation realistic? Expert Rev. Proteomics 9(4), 349–353 (2012).
- Camacho DF, Pienta KJ. Disrupting the networks of cancer. Clin. Cancer Res. 18(10), 2801–2808 (2012).
- Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput. Biol. 8(2), e1002375 (2012).
Website
- National Comprehensive Cancer Network Guidelines 2012. www.nccn.org/professionals/physician_gls/f_guidelines.asp#site